2023年8月1日

BioNTech完成550美元收購突尼斯InstaDeep加強AI-Powered藥物發現8月1日2023 BioNTech SE,著名的德國生物技術公司,發揮了關鍵作用的世界領先的Covid-19疫苗與輝瑞公司合作,取得了一個重要的裏程碑,敲定收購InstaDeep,突尼斯創業公司以其專業發展中複雜的決策算法來解決現實世界的挑戰。正式宣布的協議,今年1月,昨天成功地關閉,鞏固BioNTech的立場AI-powered藥物發現和醫學創新的最前沿。戰略並購,價值大約5億歐元,反映了BioNTech的堅定承諾,利用人工智能改變藥物的設計和開發。它持有的承諾不僅加速創建下一代免疫療法和疫苗還地址疾病與緊迫的未滿足的醫療需求,醫學領域的重要追求。作為協議的一部分,BioNTech InstaDeep的剩餘股份,不包括那些已經舉行,通過精心組織安排付款。現金支付的財務條款包含組合,BioNTech股票,和未來的支付取決於實現預定義的結果。這一戰略方法強調BioNTech審慎的商業智慧和遠見的這個聯盟的協同效應最大化。成功完成收購,InstaDeep扮演了一個新的身份倫敦子公司形成的核心BioNTech迅速擴張的舉措集中在組合的集成人工智能和機器學習在醫學領域。決定保留InstaDeep作為子公司強調BioNTech承認啟動帶來的重要價值和專業知識。BioNTech-InstaDeep夥伴關係在2019年種植的根源,和的關係繼續開花。 Acknowledging the immense potential of InstaDeep’s technology, BioNTech further solidified its commitment in January 2022 by making a strategic investment in InstaDeep’s shares during the startup’s Series B financing round, laying the groundwork for the successful acquisition today. Beyond drug development, the acquisition empowers BioNTech to extend the frontiers of artificial intelligence into other critical domains, including manufacturing. It also aligns with BioNTech’s broader initiatives, such as its recent partnership with the UK government to treat 10,000 cancer patients by 2030. Leveraging health and genome data to identify patients more swiftly, this collaboration highlights BioNTech’s dedication to addressing pressing healthcare challenges. Ugur Sahin, Chief Executive Officer of BioNTech, expressed his vision of transforming the company into a technology-driven enterprise, seamlessly integrating artificial intelligence into every facet of its work. Sahin’s leadership and dedication to innovation have been instrumental in BioNTech’s meteoric rise in the medical field. With the integration of approximately 240 new employees from InstaDeep, this acquisition represents not only a major business move but also a strategic investment in nurturing talent and expertise. It further cements BioNTech’s position as a pioneering force in AI-driven healthcare solutions and sets the stage for groundbreaking advancements in the future of drug discovery and medical research. The successful completion of the InstaDeep acquisition marks a significant chapter in BioNTech’s history, propelling the company to the vanguard of cutting-edge medical research and development. As BioNTech continues its mission to improve lives through innovation, the world eagerly anticipates the transformative impact of AI-powered healthcare breakthroughs that lie ahead. Charles Rapulu Udoh Charles Rapulu Udoh is a Lagos-based lawyer, who has several years of experience working in Africa’s burgeoning tech startup industry. He has closed multi-million dollar deals bordering on venture capital, private equity, intellectual property (trademark, patent or design, etc. ), mergers and acquisitions, in countries such as in the Delaware, New York, UK, Singapore, British Virgin Islands, South Africa, Nigeria etc. He’s also a corporate governance and cross-border data privacy and tax expert. As an award-winning writer and researcher, he is passionate about telling the African startup story, and is one of the continent’s pioneers in this regard Share this: